Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Chemed Corporation (CHE), Amedisys Inc (AMED)- For-Profit Hospices: Is Their Reliance on Medicare Funding a Liability?

Page 1 of 2

Should you as an investor be giving for-profit hospices more than a casual glance? Some statistics indicate that might be a smart move: In 1983, less than 1% of all Medicare — certified Hospice Providers were run on a for-profit basis, but by 2011, that figure had ballooned to 60%; this clearly is a growing industry.

And then, there is the fact that Medicare paid for more than 87% of all hospice expenses during 2010 and 2011, providing a secured cash flow that should inspire confidence in investors. But a hitch makes this “happy” scenario less sanguine than might originally appear to be the case.

Chemed Corporation (NYSE:CHE)

Relying upon this governmental funding has left many hospice chains vulnerable to allegations of Medicaid fraud, accusations that can prove costly even if they are eventually found to be unsubstantiated. Three companies which are leaders in that field – Chemed Corporation (NYSE:CHE), Amedisys Inc (NASDAQ:AMED), and Gentiva Health Services, Inc. (NASDAQ:GTIV) – have learned this lesson all too well.

Chemed: A possible double jeopardy

Phrases such as “end of life care” and “palliative” medicine are only now becoming part of our national lexicon. But VITAS, a division of Chemed Corporation (NYSE:CHE), first entered the hospice movement during 1978. And since that point, it has become the nation’s largest provider of hospice services; it currently operates 52 facilities and employs 9,000 professionals.

Its record has, however, been blemished by allegations of Medicare fraud related to its billing strategies and other practices. And Chemed Corporation (NYSE:CHE) shareholders seemingly find themselves to be the real “losers” in this legal fisticuffs when that company’s stock plunged 7% during one trading day after the Department of Justice sued Chemed Corporation (NYSE:CHE) for what it claimed were improprieties.

But wait, the situation gets even murkier and more twisted. As noted, VITAS remains a division of Chemed. And in addition to being the parent company of VITAS, Chemed also has a division that provides drain and plumbing cleaning services, Roto-Rooter, which has faced numerous class action law suits both from customers and from employees.

If you want to invest in VITAS, you can only do that by purchasing Chemed Corporation (NYSE:CHE) Stock, adding Roto-Rooter and any liabilities it might bring in its wake into your portfolio. Is that necessarily what you want?

Gentiva and Amedisys don’t fare as well

As was the case with Chemed, Gentiva has also encountered allegations of Medicare fraud. During October 2011, the company underwent an investigation by the Senate Finance Committee. The committee subsequently alleged that Chemed Corporation (NYSE:CHE) deliberately overscheduled visits to patients, hoping to reach a threshold for bonuses from Medicare. Amedisys Inc (NASDAQ:AMED) was the subject of these same allegations.

Page 1 of 2
Loading Comments...